iBio(IBIO)
NEW YORK, NYBiotechnology
Focus: iBio is a micro-cap public biotech focused on antibody therapies for oncology and metabolic diseases, operating with 1-50 employees and minimal commercial revenue. The company is in early-stage development with three Phase 1 programs and operates as a pre-revenue biotech with significant R&D spending relative to revenue.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
1
Should You Work at iBio?
AI assessmentiBio represents a high-risk, early-stage bet suitable only for pharma professionals comfortable with pre-revenue biotech volatility, seeking deep platform involvement, and willing to accept significant dilution and financial instability risk.
Why Work Here
- Participation in cutting-edge antibody engineering and early oncology drug development with potential for significant upside if Phase 1 programs advance.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$400K
Pipeline & Clinical Trials
IBIO-600
Overweight , ObesityClinical Trials (1)
NCT07487376A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
Phase 1Help build intelligence for iBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.